27 completed. 27 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 27 |
| Phase 2 | 3 | Completed 3 |
Follow Heartburn: new trials by email Literature Review of Heartburn trials Research Report on Heartburn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets - Functional Dyspepsia | Phase 3 | Completed | Abbott | 564 | 2024-02-28 | 2026-04-03 |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) Vonoprazan, Placebo - Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn | Phase 3 | Completed | Phathom Pharmaceuticals, Inc. | 776 | 2022-01-17 | 2023-12-29 |
| Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients Dexlansoprazole, Placebo - Heartburn, Gastroesophageal Reflux Disease | Phase 3 | Completed | Takeda | 217 | 2016-12-27 | 2019-07-05 |
| Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study Compound Sodium Alginate Double Action Chewable Tablets, Matching placebo tablets - Gastroesophageal Reflux Disease, Dyspepsia | Phase 3 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 1107 | 2013-06-05 | 2025-05-08 |
| Efficacy of Esomeprazole in Patients With Frequent Heartburn Esomeprazole - Heartburn | Phase 3 | Completed | AstraZeneca | 340 | 2011-08-01 | 2013-03-14 |
| Efficacy of Esomeprazole in Patients With Frequent Heartburn Esomeprazole - Heartburn | Phase 3 | Completed | AstraZeneca | 341 | 2011-08-01 | 2013-04-11 |
| Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease Sodium alginate, Omeprazole - Gastroesophageal Reflux Disease, Heartburn | Phase 3 | Completed | Chang Gung Memorial Hospital | 195 | 2010-10-01 | 2012-02-10 |
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial Fluoxetine, Omeprazole, placebo - Non-erosive Reflux Disease | Phase 2 / Phase 3 | Completed | Tehran University of Medical Sciences | 144 | 2010-08-01 | 2012-03-06 |
| Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients Nortriptyline, Placebo arm - Gastroesophageal Reflux Disease | Phase 3 | Completed | Universidade de Passo Fundo | 20 | 2010-01-01 | 2012-07-17 |
| Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease AGSPT201 Tab contains S-pantoprazole - Gastroesophageal Reflux Disease | Phase 3 | Completed | Ahn-Gook Pharmaceuticals Co.,Ltd | 154 | 2009-12-01 | 2011-09-21 |
| Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy Dexlansoprazole MR QD - Gastroesophageal Reflux | Phase 3 | Completed | Takeda | 178 | 2009-02-01 | 2012-02-03 |
| Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD. Pantoprazole, placebo - Gastroesophageal Reflux Disease | Phase 2 / Phase 3 | Completed | Southern Arizona VA Health Care System | 40 | 2008-04-01 | 2010-08-19 |
| A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn Dexlansoprazole, Placebo - Gastroesophageal Reflux | Phase 3 | Completed | Takeda | 305 | 2008-03-01 | 2011-04-28 |
| Efficacy and Safety of Itopride vs Placebo in Heartburn Itopride, Placebo - Heartburn | Phase 3 | Completed | Forest Laboratories | 48 | 2006-10-01 | 2017-02-09 |
| Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) nizatidine (axid), placebo - Gastroesophageal Reflux Disease, GERD | Phase 3 | Completed | Braintree Laboratories | 138 | 2006-08-01 | 2009-11-18 |
| Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn Lanzoprazole - Heartburn | Phase 3 | Completed | Novartis | 576 | 2006-06-01 | 2007-04-16 |
| Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn Lansoprazole - Heartburn | Phase 3 | Completed | Novartis | 576 | 2006-06-01 | 2010-05-25 |
| Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease Dexlansoprazole MR, Placebo - Gastroesophageal Reflux Disease | Phase 3 | Completed | Takeda | 947 | 2006-06-01 | 2011-04-28 |
| Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant - Gastroesophageal Reflux Disease | Phase 2 / Phase 3 | Completed | US Department of Veterans Affairs | 236 | 2006-04-01 | 2014-08-18 |
| Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn Dexlansoprazole MR, Placebo - Gastroesophageal Reflux Disease | Phase 3 | Completed | Takeda | 908 | 2005-12-01 | 2011-04-28 |
Showing 20 of 27. Sign in to see all of them.
Gastroesophageal Reflux (16) · Dyspepsia (3) · Esophagitis (2) · Non-Erosive Reflux Disease (2) · Abdominal Pain (1) · Anorexia (1) · Laryngopharyngeal Reflux (1) · Nausea (1) · Pain (1) · Parasomnias (1) · Vomiting (1)
Pathological Conditions, Signs and Symptoms (27) · Signs and Symptoms (27) · Signs and Symptoms, Digestive (27) · Deglutition Disorders (17) · Digestive System Diseases (17) · Esophageal Diseases (17) · Esophageal Motility Disorders (17) · Gastrointestinal Diseases (17) · Gastroenteritis (2) · Neurologic Manifestations (2) · Gastroesophageal Reflux (1) · Laryngeal Diseases (1) · Mental Disorders (1) · Nervous System Diseases (1) · Pain (1)
Dexlansoprazole (5) · Lansoprazole (5) · Rabeprazole (5) · Esomeprazole (3) · Nortriptyline (2) · Omeprazole (2) · tegaserod (2) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · Alginates (1) · Fluoxetine (1) · Nizatidine (1) · Pantoprazole (1) · Sugars (1) · itopride (1)
Takeda (5) · Novartis (4) · AstraZeneca (3) · Eisai Inc. (2) · Abbott (1) · Ahn-Gook Pharmaceuticals Co.,Ltd (1) · Braintree Laboratories (1) · Chang Gung Memorial Hospital (1) · Forest Laboratories (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen-Ortho Inc., Canada (1) · Phathom Pharmaceuticals, Inc. (1) · Reckitt Benckiser Healthcare (UK) Limited (1) · Southern Arizona VA Health Care System (1) · Tehran University of Medical Sciences (1)
United States (17) · China (2) · Armenia (1) · Brazil (1) · Canada (1) · Iran (1) · Malaysia (1) · Philippines (1) · South Korea (1) · Taiwan (1) · Thailand (1) · Vietnam (1)
Tore Lind, MD (2) · Akbar Fotouhi, MD, PhD (1) · Arash Etemadi, MD, PhD (1) · Behtash Saeidi, MD (1) · Cheng-Tang Chiu, MD (1) · HoonYong Jeong, M.D (1) · John McGowan (1) · Kaveh Hajifathalian, MD (1) · Mohammad Reza Ostovaneh, MD,MPH (1)
PMID 19735233, PMID 25141241, PMID 27331882, PMID 29788903, PMID 31297231, PMID 15233698, PMID 18561877, PMID 19392864, PMID 21129076, PMID 21224838, PMID 22155561, PMID 23451835, PMID 24024757, PMID 24118079, PMID 24533896, PMID 26228097, PMID 38750866, PMID 41081570